Skip to main content
search
 
 

Chembio Receives $1.8 Million Carb-X Grant To Develop A Rapid Diagnostic Test For Typhoid Fever

Learn More
 
 

Chembio Announces Dual FDA Submission Of DPP® Syphilis TnT Assay Following Breakthrough Device Designation

Learn More
 

CHEMBIO RECEIVES GRANT FOR DEVELOPMENT OF A RAPID POINT OF CARE TEST FOR PREECLAMPSIA

PRESS RELEASE
1
1

Announcing the receipt of CLIA Waiver for DPP HIV-Syphilis. Contact your local Chembio Representative for more information

DPP® HIV-Syphilis

CLIA Waved Badge

Stay up to date with our latest news.

Typhoid bacteria background
Chembio

CHEMBIO RECEIVES $1.8 MILLION CARB-X GRANT TO DEVELOP A RAPID DIAGNOSTIC TEST FOR TYPHOID FEVER

CHEMBIO DIAGNOSTIC SYSTEMS, INC., A BIOSYNEX SUBSIDIARY, RECEIVES $1.8 MILLION CARB-X GRANT TO DEVELOP A…
Chembio

CHEMBIO ANNOUNCES DUAL FDA SUBMISSION OF DPP® SYPHILIS TnT ASSAY FOLLOWING BREAKTHROUGH DEVICE DESIGNATION

CHEMBIO DIAGNOSTIC SYSTESMS INC., A SUBSIDIARY OF BIOSYNEX, ANNOUNCES DUAL FDA SUBMISSION OF DPP® SYPHILIS…
Chembio

CHEMBIO RECEIVES A GRANT FOR DEVELOPMENT OF A RAPID POINT OF CARE TEST FOR PREECLAMPSIA

CHEMBIO DIAGNOSTIC SYSTESMS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A…
About Us

We enable longer and healthier living through detection and monitoring of infectious diseases at the point of care.

Our mission is to be a leader in the development, manufacturing and commercialization of diagnostic solutions. We are dedicated to delivering exceptional point-of-care products that are easy to use, fast and accurate.

Our Core Values: “RAPID”

Relentless

Accountable

Passionate

Innovative

Diverse

Learn More

We are looking for talented, dedicated people wishing to contribute to our common vision of enhancing the health and well being of people worldwide.

Subscribe to the Chembio Mailing List